Home » Posts tagged 'lpa'
Tag Archives: lpa
Alan Green talks Armadale Capital #ACP, Destiny Pharma #DEST & LPA Group #LPA on Vox Markets podcast
Alan Green discusses Armadale Capital #ACP, Destiny Pharma #DEST & LPA Group #LPA with Justin Waite on the Vox Markets podcast. We also talk about Maddi’s Butterflies Children’s Cancer Charity Caravan appeal.
LPA Group plc LPA reports that he last financial year was exceptionally strong and something of a blockbuster which it finished at a gallop with record output. The new financial year then started with a record order book and a major contract win the award of the contract for the upgrade of the lighting on London’s Central and Waterloo & City lines rolling stock. The contract is worth 4m. to 2023 and also has an ongoing through-life support contract to 2043. The rail market remains very buoyant, with huge commitments by Government attracting massive inward investment which potentially promises a bonanza. Despite 2018’s strong performance the current financial year is expected to see a return to more regular levels of activity.
Hiscox plc HSX has enjoyed strong growth during the 9 months to the 30th September with gross written premiums rising by 14.3%. As markets remain challenging however, this is expected to moderate over the remainder of the year. The results were impacted by catastrophes in the US and the Far East as well as by a number of larger individual claims. Plans for Brexit are well advanced and have always assumed a worst-case scenario ‘hard Brexit’ and for that the company is prepared, irrespective of the outcome of the government’s negotiations. So much for the relevance of politicians.
Totally plc TLY The first half of the current year has been a transformational period for the group with interim results showing turnover rising to over 40,000,000 from 3,530,000 last year. In excess of £10m new business and renewed contracts have been announced since the previous results announcement on the10 July. The Chancellor’s announcement of an increase in NHS funding of £20.5 billion over a 5 year period will no doubt help the transformation continue.
WANdisco WAND has secured a contract with the leading information and communications technology provider in China. The contract is valued at $1 million part of which will be recurring. The company says that the Chinese market represents a significant untapped opportunity.
Versarien VRS Yesterday signed a Framework Agreement with the Qingdao Municipal Bureau of Commerce in Shandong Province, China, covering cooperation between the parties in the fields of graphene research, development and industrialisation. Qingdao, is a major city in Shandong Province, China, with a population of over nine million people and is one of the major areas of graphite production in China.
Buy LPA Group #LPA says VectorVest. This relatively anonymous co might just be one of the big stock market successes in 2018
Suffolk-based LPA Group Plc (LPA.L) specialises in the design and assembly of LED based lighting and electronic systems and is one of the leading electromechanical systems manufacturers across the globe. The Company has a strong reputation for innovation winning several awards including the Rail Business Award for Environmental Innovation for its LED based LumiPanel® lighting product. LPA employs around 200 people at four locations in the UK and exports to nearly fifty countries.
Examine this trading opportunity and a host of other similar stocks. A single payment of £5.95 gives access to the VectorVest Risk Free 30-day trial. More here
On January 23rd 2018, LPA announced record results for the year ended 30 Sept 2017 and a strong start to the new financial year. Sales rose by 4.9% to £22.48m, generating a 26.3% hike in PBT to £1.91m. Basic EPS rose by 17.1% to 14.40p, gearing fell to 25.7% (2016: 29.2%) while the order book rose by 20% to £21.6m. The final dividend increased 10% to 1.65p, totaling 2.70p for the year (2016: 2.50p). CEO Peter Pollock said the 2016 financial year “marked a step change in the performance of the Group, and these record results for the 2017 financial year are confirmation that we are now established at this substantially increased level of activity. “ He added; “We look forward to continuing progress this year and for the future.”
The record numbers revealed in the FY results triggered alerts across VectorVest metrics as far back as November 2017. Today, the VST (VST-Vector) indicator, (the master indicator for ranking every stock in the VectorVest database), rates LPA at 1.26, which is very good on a scale of 0.00 to 2.00. Added to this, the GRT (forecasted Earnings Growth Rate) for LPA logs at 16.00%, which again is considered a very good rating on the VectorVest stock analysis and portfolio management system. GRT reflects a company’s one to three year forecasted earnings growth rate in percent per year. VectorVest logs a current value of 219p per share for LPA, so at the current 171p the stock can be considered as undervalued.
The chart of LPA.L is shown above in my usual format. Earnings per share (EPS is growing strongly and the share is on a BUY recommendation on VectorVest. Technicians will have noted the cup and handle formation. This is a highly reliable bullish pattern which gave a buying signal above a price of 165p.
Summary: The never-ending VectorVest quest to identify ‘under the radar’ quality growth companies may just have come up trumps again with LPA. Trifast (TRI.L) was identified as a highly cash generative, albeit relatively anonymous growth play as far back as mid 2016. LPA exhibits many of the same qualities, in terms of earnings and dividend growth, but somewhat surprisingly the current market cap is less than the turnover for the last financial year. This relatively anonymous lighting and electrical group sells to an enviable blue chip client list, has won many prestigious awards and might just be one of the big stock market successes in 2018. Buy.
Dr David Paul
January 24 2018
Readers can examine trading opportunities on LPA and a host of other similar stocks for a single payment of £5.95. This gives access to the VectorVest Risk Free 30-day trial, where members enjoy unlimited access to VectorVest UK & U.S., plus VectorVest University for on-demand strategies and training. Link here to view.
On VectorVest a simple search using the Unisearch tool will quickly find shares that are undervalued with good fundamentals that have just issued a Buy recommendation. This will give the active trader a short list of many high probability trading opportunities each week. Traders now have the opportunity to spend five weeks discovering VectorVest’s unique simplicity, automation and independent guidance. Just £5.95 buys a 5 week trial to enable deep exploration, or how the system can assist in smarter trading in as little as 10 minutes a day. Powerful tools. Proven strategies. Unique Perspectives.
Link here for more info and to set up a trial.
European Financial Publishing Limited T/A VectorVest UK (VectorVest) is authorised and regulated by the Financial Conduct Authority under register number 543038. You should remember that the value of investments and the income derived therefrom may fall as well as rise and you may not get back the amount that you invest. Past performance is not a reliable guide to the future. This material is directed only at persons in the UK and is not an offer or invitation to buy or sell securities. If investors are in any doubt of the suitability of an investment given their individual circumstances, they are recommended to contact an investment manager or independent financial adviser who may be able to provide tailored advice. Opinions expressed whether in general or both on the performance of individual securities and in a wider economic context represent the views of VectorVest at the time of preparation. They are subject to change and should not be interpreted as investment advice. VectorVest and connected companies, clients, directors, employees and other associates, may have a position in any security, or related financial instrument, issued by a company or organisation mentioned on this site. European Financial Publishing Limited is a company incorporated in Scotland under Company Number SC357322 with its registered address at Exchange Tower, 19 Canning Street, Edinburgh EH3 8EH. Email: support@VectorVest.comFREE! For free VectorVest analysis on any stock, go to this link here
Brand CEO Alan Green talks URA Holdings #URA, Tertiary Minerals #TYM & LPA Group #LPA on VOX Markets podcast.
Brand CEO Alan Green discusses URA Holdings #URA, Tertiary Minerals #TYM and LPA Group #LPA with Justin Waite on the VOX Markets podcast. The interview is 21 minutes in.
Bilby plc BILB With revenue doubling in the year to 31st March and gross profit rising from £6m. to £11.02m., Bilby has established itself as the largest gas contractor in London and the South East. However after various non underlying items, profit before tax fell from a restated £0.72m in 2016 to this years £0.06m. On an adjusted basis last years basic earnings per share of 5.34p has increased to 7.66p. The annual dividend is to be 2.2p per share compared to a restated 2.75p. per share for 2016.
Advanced Oncotherapy AVO announces another year of significant progress and development in the commercialisation of its next-generation technology in the treatment of cancer – LIGHT. Despite some challenges and obstacles during the year to the end of December, these have been overcome and the company looks forward to successfully executing the timelines that were outlined in March 2017. Since the year end, management has been strengthened and significant technical milestones have been reached. New finance has also been agreed and secured.
LPA Group LPA claims that the excellent levels of orders and sales announced at the AGM, has continued through the half year to 31st March. Profit before tax has risen from £782,000 to £976,000 on revenue up by 3.1% Diluted earnings per share are up from 5.34p to 6.81p per share. The interim dividend is to be raised by 5% to 1.05p per share.However despite those claims about the excellence of the order book, it stands at £22m., exactly where it was at half time, a year ago.
Quantum Pharma plc QP. announces the disposal of its homecare and dispensary business enabling it to focus on its Niche and Specials divisions and eliminate low margin turnover.The Niche & Specials divisions have been trading ahead of plan in the early months of the year and the outperformance here is expected to offset the majority of the loss from the division which is being disposed of.